Hematopoietic stem cell therapy for malignant diseases

ArticleinAnnals of Medicine 39(6):465-73 · February 2007with4 Reads
Impact Factor: 3.89 · DOI: 10.1080/07853890701472323 · Source: PubMed


    Allogeneic bone marrow or blood stem cell transplantation (SCT) has changed its face in the last two decades. The introduction of nonmyeloablative conditioning regimens has reduced procedure toxicity and allowed the application of SCT in patients and conditions in which SCT was not offered in the past. In this review we will summarize the changes and accomplishments achieved in the past years in the field of stem cell transplantation for malignant disorders.

    Similar publications